December Nasdaq 100 E-Mini futures (NQZ23) are trending up +0.44% this morning as U.S. Treasury yields slipped from decade highs, while investors braced for a new round of economic data as well as an earnings...
Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean...
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...
Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses...
BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...
GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor GALACTIC-1 trial on track to deliver top-line results in mid-2023...
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022 Part 1 of GULLIVER-2 trial completed with positive results as previously...
UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.